Ranbaxy Launches Antiplatelet Agent Prasugrel in India

Daiichi Sankyo Company Limited (“Daiichi Sankyo”) and Ranbaxy Laboratories Limited (“Ranbaxy”) announced today that Ranbaxy has launched a generic version of Prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Prasita is solely marketed by Ranbaxy in India.

Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive originally discovered by Daiichi Sankyo, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India through the strong Ranbaxy business network. Ranbaxy will create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.

“We are pleased to be able to introduce Prasita in India,” said Atul Sobti, CEO and Managing Director of Ranbaxy. “A number of synergy projects between Ranbaxy and Daiichi Sankyo are already underway, and we will further strengthen our common endeavour to realise greater benefits from our Hybrid Business Model.”

“The launch of our two top flagship products, olmesartan medoxomil and prasugrel, by Ranbaxy shows our serious commitment to India, and we will continue to explore further collaborations leveraging the Hybrid Business Model,” said Takashi Shoda, President & CEO of Daiichi Sankyo.

About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com